Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012, 156(3):200-203 | DOI: 10.5507/bp.2012.049

The role of BRCA1 in non-small cell lung cancer

Mariam Gachechiladze, Josef Skarda
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Background:  BRCA1 (Breast cancer 1) was previously identified as a breast and ovarian cancer susceptibility gene, but recently gained a major scientific interest as a prognostic and/or predictive marker for various tumors, including non-small cell lung cancer (NSCLC), which is the leading cause of cancer related mortality in the world. We aimed to review the role of BRCA1 in NSCLC based on currently available literature.



Methods: We performed the literature search in Pubmed database, using key words: BRCA1, non small cell lung cancer, chemotherapy, drug resistance. Articles published in English were selected for review.



Results: Research papers are mainly focused on BRCA1 mRNA expression studies in response to DNA damaging chemotherapy. Several articles about genetic and epigenetic changes of BRCA1 in NSCLC were also available.



Conclusions: BRCA1 is a multifunctional tumor supressor protein, which plays a key role in essential cellular processes and modulates the cellular response to cytotoxic chemotherapy. With the difference from breast and ovarian cancer, BRCA1 has no role in NSCLC cancerogenesis and mainly discussed as a promising genomic marker for customized chemotherapy in NSCLC patients.

Keywords: BRCA1, non-small cell lung cancer, chemotherapy

Received: September 8, 2011; Accepted: April 13, 2012; Prepublished online: June 1, 2012; Published: September 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Gachechiladze, M., & Skarda, J. (2012). The role of BRCA1 in non-small cell lung cancer. Biomedical papers, 156(3), 200-203. doi: 10.5507/bp.2012.049
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA: A Cancer Journal for Clinicians 2008;58:71-96. Go to original source... Go to PubMed...
    2. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003;21:3016-24. Go to original source... Go to PubMed...
    3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A,Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3543-51. Go to original source... Go to PubMed...
    4. Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, Pignon JP. Second or third additional chemo­therapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;4:CD004569. Go to original source... Go to PubMed...
    5. Rosen EM, Fan S, Isaacs C. BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocrine-Related Cancer 2005;12(3):533-48. Go to original source... Go to PubMed...
    6. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Molecular Cancer Therapeutics 2006;5(6):1396-1404. Go to original source... Go to PubMed...
    7. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998;8:283-9. Go to original source... Go to PubMed...
    8. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. A. Crossstudy comparison of gene expression studies for the molecular classification of lung cancer. Clinical Cancer Research 2004;10:2922-7. Go to original source... Go to PubMed...
    9. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, Kratzke R, Watson MA, Kelley M, Ginsburg GS, West M, Harpole DH, Nevins JR. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New England Journal of Medicine 2006;355:570-80. Go to original source... Go to PubMed...
    10. Carmen J, Marsit CJ, Liu M, Nelson HH , Posner M, Suzuki M, and Kelsey K T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23,1000-4. Go to original source... Go to PubMed...
    11. Lee M, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, Wang YC. Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non-Small Cell Lung Cancer. Clinical Cancer Research 2007;13:832-8. Go to original source... Go to PubMed...
    12. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of non small cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008;6:1325-36. Go to original source... Go to PubMed...
    13. Damsma GE, Alt A, Brueckner F, Carell T, Cramer P. Mechanism of transcriptional stalling at cisplatin-damaged DNA. Nature Structural and Molecular Biology 2007;12:1127-33. Go to original source...
    14. Basu A, Krishnamurthy S. Cellular Responses to cisplatin-induced DNA damage. Journal of nucleic acids 2010;2010:1-16. doi:10.4061/2010/201367 Go to original source...
    15. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development 2000;14:927-39. Go to original source... Go to PubMed...
    16. Yang ES, Xia F. BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS Journal 2010;277(15):3079-85. Go to original source... Go to PubMed...
    17. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Quralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics2004;13(20):2443-9. Go to original source... Go to PubMed...
    18. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki MM, Staphopoulos E, Georgoulias V, Rosell R , Souglakos J. Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. PLoS ONE2008;3(11):e3695. Go to original source... Go to PubMed...
    19. Wang L, Wei J, Qian X, Yin H, ZhaoY, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008;8:97. Go to original source... Go to PubMed...
    20. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida F, Farabi R, Jassem J. BRCA1: a novel prognostic factor in resected nonsmall-cell lung cancer;. PLoS One2007;2:e1129. Go to original source... Go to PubMed...
    21. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, Penas R, Catot S, Isla D, JM Sanchez, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M. Customized treatment in nonsmallcell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One2009;4:e5133. Go to original source... Go to PubMed...
    22. Tiseo M, Bordi P, Bortesi B. ERCC 1/BRCA1 protein expressions and ERCC1/ XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin. Journal of Thoracic Oncol 2009;4:D7.5.
    23. Wachtersa FM, Wong LSM. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-9. Go to original source... Go to PubMed...
    24. Shuji Ota, Genichiro Ishii, Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.. Lung Cancer 2009;64:98-104. Go to original source... Go to PubMed...
    25. Kanga CH, Jangb BG, Kimc DW, Chungb DH, Kima YT, Jheond S, Sungd CW, Kima JH. The prognostic significance of ERCC1, BRCA1, XRCC1, and βIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer2010; 68(3):478-83. Go to original source... Go to PubMed...

    Return to the content